Table 1 Baseline characteristics and outcomes (n = 49).
Characteristic | Number (%) or Median (Range) |
|---|---|
Age (in years) | 24 (6–68) |
Male sex | 39 (79.5) |
Disease type | |
1. Primary refractory disease | 9 (18.3) |
2. Very early/early relapse | 24 (48.9) |
3. Late relapse | 9 (18.3) |
4. Post-transplant relapse | 7 (14.2) (1 CR1, 5 CR2 and 1 CR3 transplant) |
Cytogenetics | |
Normal | 24 (48.9) |
Abnormal | 22 (44.9) |
1. Ph+ve (n = 6) | |
2. High Risk Cytogenetics (n = 8) (Hypodiploidy (n = 2), Complex karyotype (n = 5), KMT2Ar (n = 1)) | |
3. Others (n = 8) | |
Not Available | 3 (6.2) |
Extent of disease prior to InO | |
1. Peripheral blood WBC count | 4600 per cu.mm (600–12200) |
2. Proportion of peripheral blasts on morphology | 0 (0–79) |
3. Proportion of marrow blasts on morphology | 44 (8–92) |
4. CNS disease | 6 (12.2) |
5. Testicular disease | 1 (2) |
Pattern of InO use | |
1. Single agent InO | 43 (87.7) |
2. Single agent InO with triple intrathecal | 2 (4) |
3. Along with chemotherapy/other agents | 4 (2–Mini-HyperCVAD, 2–Dasatinib) (8.1) |
Median number of doses of InO used | 3(1–12) |
Line of salvage of InO | |
1. First line | 4 (8.1) |
2. Second line | 19 (38.7) |
3. Third or later | 26 (53) |
Response to salvage InO | |
1. Not assessed | 5 (10.2) |
2. Remission | 28 (57.1) (of which 20 were MRD negative) (Median doses of InO – 4(2–12)) |
3. No response | 16 (32.6) (Median doses of InO – 3 (2–9)) |
Subsequent treatment following response (N = 28) | |
Hematopoietic stem cell transplantation | 18 (64.3) |
CAR T | 1 (3.6) |
Causes of Death | |
1. Death due to progressive disease | 13 (26.5) |
2. Death while in remission | 11 (22.4) (Sepsis (8), SOS (1), and cerebrovascular accident (2)) |
Median follow-up of the entire cohort from initiation of InO | 6 (1–41) months |
Median follow-up of the surviving patients | 10.5 (2–24) months |
